Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a clinical-stage biotechnology company focused on developing innovative therapies for cancer and other serious diseases, announced that its CEO and Chairman, Dr. Vuong Trieu, will present at the OTCQB Virtual Investor Conference on August 6, 2026, at 2:30 p.m. ET. The presentation will include a live question-and-answer session, giving investors an opportunity to engage directly with the company's leadership.
The company will highlight several key developments that underscore its progress and strategic direction. Notably, Oncotelic has advanced its Phase 1b intravenous Everolimus (Sapu003) trial to the next dose cohort, a significant step in evaluating the safety and efficacy of this potential cancer treatment. Additionally, the company has expanded its European clinical sites, enhancing its ability to conduct trials across multiple regions and accelerate patient recruitment.
A major focus of the presentation will be the validation of Oncotelic's Deciparticle platform through peer-reviewed publications. This proprietary drug delivery technology is designed to improve the therapeutic index of existing drugs, potentially leading to better patient outcomes. The company has also demonstrated scalable cGMP manufacturing capabilities, ensuring that its therapies can be produced at commercial scale when approved.
Oncotelic continues to invest in cutting-edge technologies, including AI-driven drug discovery, robotics, and nanomedicine platforms. These initiatives aim to streamline the drug development process and bring novel treatments to market more efficiently. By integrating artificial intelligence and automation, the company hopes to identify promising drug candidates faster and reduce the costs associated with traditional research and development.
The OTCQB Virtual Investor Conference provides a platform for publicly traded companies to share their stories with a broad audience of investors. Oncotelic's participation reflects its commitment to transparency and investor engagement. The company's presentation is expected to offer insights into its pipeline, milestones, and future plans.
For more information about Oncotelic Therapeutics and its latest updates, interested parties can visit the company's newsroom at https://nnw.fm/OTLC. The full press release regarding this announcement is available at https://nnw.fm/fGHUt.
Oncotelic Therapeutics is dedicated to advancing precision medicine and RNA therapeutics to address unmet medical needs. With a robust portfolio of clinical-stage oncology assets and a focus on innovative delivery technologies, the company is well-positioned to make meaningful contributions to cancer care. The upcoming presentation at the OTCQB conference will serve as a platform to communicate its vision and recent achievements to the investment community.
